O
Oruka Therapeutics, Inc. (ORKA)
NGM – Real Time Price. Currency in USD
44.48
-0.98 (-2.16%)
At close: Mar 27, 2026, 4:00 PM EDT
44.20
-0.28 (-0.63%)
After-hours: Mar 27, 2026, 7:45 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
44.48
-0.98 (-2.16%)
At close: Mar 27, 2026, 4:00 PM EDT
44.20
-0.28 (-0.63%)
After-hours: Mar 27, 2026, 7:45 PM EDT
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Name | Position |
|---|---|
| Dr. Joana Goncalves M.D. | Chief Medical Officer |
| Dr. Lawrence Otto Klein Ph.D. | President, CEO & Director |
| Mr. Alan Lada | Vice President of Investor Relations |
| Mr. Arjun Agarwal CPA | Senior VP of Finance & Treasurer |
| Mr. Paul T. Quinlan | General Counsel & Secretary |
| Ms. Laura Sandler | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-12 | 10-K | ea0273300-10k_oruka.htm |
| 2025-12-11 | 8-K | ea0268925-8k_oruka.htm |
| 2025-11-12 | 10-Q | ea0262412-10q_oruka.htm |
| 2025-10-03 | S-3 | ea0260073-s3_oruka.htm |
| 2025-09-22 | 8-K | ea0257865-8k_oruka.htm |
| 2025-08-11 | 10-Q | ea0250224-10q_oruka.htm |
| 2025-07-01 | 8-K | ea0247670-8k_oruka.htm |
| 2025-06-03 | 8-K | ea0244429-8k_oruka.htm |
| 2025-05-14 | 10-Q | ea0239898-10q_oruka.htm |
| 2025-04-18 | DEF 14A | ea0237916-01.htm |